... biopharmaceutical company's stock valued at $100,000 after acquiring an additional 140 shares in the last quarter. Ardsley Advisory Partners lifted its position in shares of CymaBay Therapeutics by 66.2% in the second quarter. Ardsley Advisory ...
http://ift.tt/2itY4zR
No comments:
Post a Comment